Overview

A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

Status:
Completed

Trial end date:
2019-04-04

Target enrollment:

Participant gender:

Summary

To evaluate the safety and exploratory efficacy of 1.0mg of Luminate® in patients with Intermediate Non-Exudative Macular Degeneration

Phase:

Phase 2

Details

Lead Sponsor:

Allegro Ophthalmics, LLC